Ipratropium Enfants Zentiva

Ipratropium bromide, the active ingredient in Ipratropium Enfants Zentiva, is an anticholinergic (muscarinic antagonist) presented as an inhalation solution for inhalation use. It is indicated for the treatment of chronic obstructive pulmonary disease (COPD) and asthma in pediatric patients by causing bronchodilation and reducing airway resistance.

GNH USA supplies Ipratropium Enfants Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide, with a focus on quality assurance and regulatory compliance.

Ipratropium bromide is a bronchodilator that acts on the airway smooth muscle to improve airflow in chronic respiratory conditions.

- Chronic Obstructive Pulmonary Disease (COPD): improves lung function and reduces bronchoconstriction. - Asthma: provides bronchodilation for symptom relief and prevention of exacerbations. - Bronchospasm associated with COPD or asthma: rapidly relaxes airway smooth muscle to ease breathing.

Ipratropium bromide may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Cough: transient irritation of the airway. - Dry mouth: reduced salivary secretion. - Throat irritation: mild soreness after inhalation. - Hoarseness: temporary voice changes. - Headache: mild, often resolves. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing. - Allergic reactions: rash, urticaria, or angioedema. - Tachycardia: increased heart rate. - Urinary retention: difficulty emptying the bladder. - Severe airway irritation: persistent cough or wheeze. - Anaphylaxis: rare life‑threatening hypersensitivity.

When prescribing Ipratropium bromide, clinicians should consider the following precautions.

- Assess lung function before initiation: ensure appropriate diagnosis and baseline measurements. - Monitor for anticholinergic effects: watch for dry mouth, urinary retention, or blurred vision. - Use with caution in narrow‑angle glaucoma: intra‑ocular pressure may increase. - Avoid in patients with severe urinary obstruction: risk of retention. - Do not combine with other anticholinergic inhalers without supervision: may amplify side effects. - Store at room temperature: keep in original container, protect from moisture and direct heat.

Ipratropium bromide can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concurrent use of other anticholinergic inhalers (e.g., tiotropium): may increase anticholinergic load and side‑effects. - Combination with potent beta‑agonists in high doses: risk of excessive bronchodilation and tachycardia.

Moderate Interactions (Monitor Closely):\n- Use with ocular antihistamine drops: may exacerbate dry eye symptoms. - Concomitant use of drugs that cause urinary retention (e.g., antihistamines): monitor bladder function. - Co‑administration with systemic anticholinergics (e.g., atropine): observe for additive systemic effects.